Medical Tidbits, Merck KGaA, Darmstadt, Germany and Pfizer to Present Updates for Avelumab at the European Cancer Congress 2015

Your place for beaking medical news and career advice from top medical recruiters

Research in Medical Field

DARMSTADT, Germany & NEW YORK–(EON: Enhanced Online News)–Merck KGaA, Darmstadt, Germany and Pfizer today announced that six abstracts on studies evaluating the potential role of programmed death-ligand 1 (PD-L1) inhibition and the safety and efficacy of the investigational cancer immunotherapy avelumab* will be presented at this year’s ECC in Vienna, Austria, September 25–29, 2015.  read more

Allergan And Perrigo Receive FDA Approval Of Three Extended Release Products Equivalent To MucinexMucinex® DM

DUBLIN, Sept. 10, 2015 /PRNewswire/ — Allergan plc (NYSE: AGN) and its partner Perrigo Company plc (NYSE: PRGO; TASE) announced today that Allergan has received U.S. Food and Drug Administration (FDA) approval for its Abbreviated New Drug Applications for three Mucinex® equivalent products. read more


Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and its diagnostics subsidiary EIDIA Co., Ltd. (Headquarters: Tokyo, President: Atsushi Saito, “EIDIA”) announced today that EIDIA will launch HISCL KL-6 , a new diagnostic kit to detect marker for interstitial pneumonia, in Japan on September 16, 2015. read more

Pilot Study Shows Positive Results for Treatment of Pancreatic Cancer

CHICAGO–(EON: Enhanced Online News)–Tiny gas microbubbles can enhance the delivery and absorption of cancer drugs in patients with advanced pancreatic cancer, according to a pilot study update described at the International Contrast Ultrasound Society (ICUS) annual conference today in Chicago.  read more

Puma Biotechnology Announces Publication of PB272 in HER2 Non-Amplified Metastatic Breast Cancer with a HER2 mutation

LOS ANGELES–(BUSINESS WIRE)–Puma Biotechnology, Inc. (NYSE: PBYI), today announced a publication in the September 2015 issue of the Journal of the National Comprehensive Cancer Network describes that a patient with HER2 non-amplified (HER2-negative) metastatic breast cancer who also had a HER2 activating mutation was successfully treated with PB272 (neratinib). read more

Boston Scientific Announces CE Mark for the Vercise™ Primary Cell Deep Brain Stimulation System, System Includes First Directional Lead with Current Steering and Expanded Programming Flexibility

MARLBOROUGH, Mass., Sept. 10, 2015 /PRNewswire/ — Boston Scientific (NYSE: BSX) has received CE Mark for the Vercise™ Primary Cell (PC) Deep Brain Stimulation (DBS) System. The Vercise PC System is intended to provide precise neural targeting to address the varying needs of patients suffering from Parkinson’s disease (PD), primary and secondary dystonia, and essential tremor. The System is a non-rechargeable treatment option that also powers the Vercise DBS Directional Lead, the first commercially available eight-contact segmented lead with current steering. read more

Biogen Prices $6.0 Billion of Senior Unsecured Notes

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Biogen (NASDAQ: BIIB) announced today the pricing of four series of senior unsecured notes for an aggregate principal amount of $6.0 billion. The notes will mature as follows: read more

NxStage and Spindial Announce Partnership with Niguarda-Ca’ Granda Hospital in Milan  

LAWRENCE, Mass., Sept. 11, 2015 /PRNewswire/ — NxStage Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of dialysis products and Spindial S.p.A., a distributor of renal care products in Italy, announced today their new partnership with the Niguarda-Ca’ Granda hospital in Milan, Italy read more

Isis Pharmaceuticals’ Collaboration to Discover and Develop Antisense Drugs for Cardiovascular, Metabolic and Renal Diseases with AstraZeneca Receives HSR Clearance

CARLSBAD, Calif., Sept. 11, 2015 /PRNewswire/ — Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) today announced that its collaboration with AstraZeneca to discover and develop antisense drugs for cardiovascular, metabolic and renal diseases has received clearance under the Hart-Scott-Rodino Antitrust Improvements Act.  AstraZeneca will pay Isis a $65 million up-front payment. Isis is eligible to receive development and regulatory milestones for each program that AstraZeneca advances to clinical development.  Isis Pharmaceuticals is also eligible to earn tiered double-digit royalties on annual net sales for each program.


Subscribe today for leading medical news and career advice from top medical recruiters!

Subscribe today for leading medical news and career advice from top medical recruiters!


Get Med Career News in your Inbox!

If you want to keep up with the latest news and career tips in the Medical Field subscribe today!

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.